A phase I clinical trial on intratumoral (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma

Schwarze, J. K. (Speaker), Vanbinst, A. (Contributor)

Activiteit: Talk or presentation at a conference

Periode2020 → …
EvenementstitelESMO Immuno-Oncology Virtual Congres
EvenementstypeConference